44 related articles for article (PubMed ID: 1296148)
1. [Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis].
Lobianco R; Merola B; Lupoli G; Cocca A; Guarino M; Pia M; Guerriero S; Lombardi G
Minerva Endocrinol; 1992; 17(2):79-84. PubMed ID: 1296148
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
3. [Comparative analysis of therapeutic effects of carbocalcitonin and and conjugated estrogens in post-menopausal osteoporosis].
Surico N; Tavassoli K
Minerva Ginecol; 1990 Dec; 42(12):529-37. PubMed ID: 2089296
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
[TBL] [Abstract][Full Text] [Related]
5. [Experience with ipriflavone therapy in postmenopausal osteoporosis].
Szántó F
Orv Hetil; 1997 Nov; 138(44):2801-3. PubMed ID: 9411349
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of ovariectomized patients with intramuscular and nasal-spray synthetic calcitonin].
Zara C; Perotti F; Ferraro R; Lauri A; Saviotti C; Montrasio MG; Caprotti M; Polatti F
Minerva Endocrinol; 1989; 14(1):53-6. PubMed ID: 2733647
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of calcitonin tolerance after intramuscular or intranasal administration in treatment for postmenopausal osteoporosis].
Horst-Sikorska W; Ruszkowska J; Kosowicz J
Przegl Lek; 1996; 53(1):9-11. PubMed ID: 8711177
[TBL] [Abstract][Full Text] [Related]
8. The effect of calcitonin treatment on plasma nitric oxide levels in post-menopausal osteoporotic patients.
Taş N; Aricioglu A; Erbas D; Ozcan S
Cell Biochem Funct; 2002 Jun; 20(2):103-5. PubMed ID: 11979505
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
[TBL] [Abstract][Full Text] [Related]
10. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
12. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
[TBL] [Abstract][Full Text] [Related]
13. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture.
Huusko TM; Karppi P; Kautiainen H; Suominen H; Avikainen V; Sulkava R
Calcif Tissue Int; 2002 Dec; 71(6):478-84. PubMed ID: 12370798
[TBL] [Abstract][Full Text] [Related]
15. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
[TBL] [Abstract][Full Text] [Related]
16. [The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis].
Abate G; Taormina F; Brillante C; Fraccalaglio L
Minerva Med; 1994 May; 85(5):253-9. PubMed ID: 8028755
[TBL] [Abstract][Full Text] [Related]
17. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
18. New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
Moscarini M; Patacchiola F; Spacca G; Palermo P; Caserta D; Valenti M
Gynecol Endocrinol; 1994 Sep; 8(3):203-7. PubMed ID: 7847106
[TBL] [Abstract][Full Text] [Related]
19. [Medium- and long-term effects of various treatment schedules with nasal S-calcitonin spray].
Maini M; Bozzi M; Brignoli E; Felicetti G
Minerva Med; 1995 Mar; 86(3):121-7. PubMed ID: 7603607
[TBL] [Abstract][Full Text] [Related]
20. The future of ipriflavone in the management of osteoporotic syndromes.
Avioli LV
Calcif Tissue Int; 1997; 61 Suppl 1():S33-5. PubMed ID: 9263615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
